

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Previously Presented) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:333.
- 3.-10. (Canceled)
11. (Previously Presented) A composition comprising the polypeptide of claim 2 in combination with a pharmaceutically acceptable carrier or excipient.
- 12.-30. (Canceled)
31. (Currently Amended) A composition comprising a ~~the~~ polypeptide according to claim 2 and monophosphoryl lipid A.
- 32.-34 (Canceled)
35. (Previously Presented) A composition comprising the polypeptide of claim 2 in combination with a non-specific immune response enhancer.
36. (Previously Presented) The composition according to claim 35 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.
37. (Canceled)

38. (Previously Presented) The composition according to claim 31, further comprising an aluminum salt.

39. (Currently Amended) A composition comprising a ~~the~~ polypeptide according to claim 2 and 3-de-O-acylated monophosphoryl lipid A.

40. (Currently Amended) The composition according to claim 40~~39~~, further comprising an aluminum salt.

41. (Currently Amended) A composition comprising a ~~the~~ polypeptide according to claim 2 and an adjuvant containing monophosphoryl lipid A.